Adam Feinstein  Barclays Capital The buy side says: “He makes a case with conviction.”

Barclays Capital’s Adam Feinstein, who captures the crown for a seventh year running, “studies the sector and the companies from every angle, and backs up his recommendations with plenty of data and well-­reasoned arguments,” proclaims one portfolio manager. The 39-year-old analyst reiterated his overweight rating on ­Universal Health Services in September 2010, at $33.13, making the case that the King of ­Prussia, Pennsylvania–based operator of behavioral health centers would streamline costs and bolster its bottom line through its acquisition of ­Psychiatric Solutions of Franklin, Tennessee. (The deal closed in November.) In July the company reported that year-over-year net revenue had advanced 41.6 percent in the first six months of 2011, to $3.8 billion, and said the increase “was due primarily to the revenues generated” at the facilities it acquired from ­Psychiatric Solutions. By the end of August, Universal Health’s shares had shot up 25.6 percent, to $41.60, outperforming the broad market by 14 percentage points.